On April 29, 2019 Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review operating results for the first quarter ended March 31, 2019 and updated, preliminary primary and new secondary endpoint data from the Phase 3 VISTA trial of Vicinium for patients with high-risk non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin (Press release, Sesen Bio, APR 29, 2019, http://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-host-conference-call-review-first-quarter-2019 [SID1234535438]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to conference ID 7176228. The webcast can be accessed in the Investor Relations section of the Company’s website at www.sesenbio.com. The replay of the webcast will be available in the investor section of the Company’s website at www.sesenbio.com for 60 days following the call.